Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Green C, Porter C, Bresnahan D, Spertus J
. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35(5):1245-55.
DOI: 10.1016/s0735-1097(00)00531-3.
View
2.
Hegde S, Lester S, Solomon S, Michels M, Elliott P, Nagueh S
. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021; 78(25):2518-2532.
DOI: 10.1016/j.jacc.2021.09.1381.
View
3.
Nassif M, Fine J, Dolan C, Reaney M, Addepalli P, Allen V
. Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. 2022; 10(8):531-539.
DOI: 10.1016/j.jchf.2022.03.002.
View
4.
Spertus J, Fine J, Elliott P, Ho C, Olivotto I, Saberi S
. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10293):2467-2475.
DOI: 10.1016/S0140-6736(21)00763-7.
View
5.
Olivotto I, Oreziak A, Barriales-Villa R, Abraham T, Masri A, Garcia-Pavia P
. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396(10253):759-769.
DOI: 10.1016/S0140-6736(20)31792-X.
View